Table 5. Average % glycan values of significantly altered peaks between COAM-treated versus control (PBS ip).
| WAX - HPLC | HILIC | |||||||||||||||||||||||||||||||||||||
| Peak S4 | Peak S3B | Peak S2 | Paek 18 | Peak 17 | Peak 15 | Peak 14 | Peak 12 | Peak 11 | Peak 10 | Peak 9 | Peak 8 | Paek 7 | Paek 6 | Peak 5 | Peak 4 | Peak 3 | Peak 2 | Peaks | ||||||||||||||||||||
| Tetrasialylated triantennary | Trisialylated biantennary | Disialylated biantennary | A3G3S(3,3,6,6)4+FA3G3S(3,3,3,6)4 | FA3G3S(3,6,6)3+A3G3S(3,3,3,6)4 | A3G3S(3,3,6)3 | A3G(4)S(3)3 | A2G [3], [4]S(3,6,6)3+FA2G [3], [4]S(3,3,6)3 | FA2G2S(6)2+A2G(3,4)2S(3,3,6)3 | A2G2S(6)2+FA2G2S(3,6)2 | A2G2S(3,6)2+FA2G2S(3)2 | A2G2S(3)2 | M5A1G1S(6)1+FA2G2S(6)1 | A1G1S(6)2 | A2G2S(6)1 | M4A1G1S(6)1 | A2G1S(6)1 | M6, A1G1S(6)1 | Abbreviation | C COAM-treated versus control (PBS ip) | |||||||||||||||||||
| Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group 5 | Group 4 | Group | ||
| 2.83 | 2.69 | 12.89 | 13.38 | 63.61 | 63.90 | 0.74 | 0.76 | 1.81 | 1.89 | 2.15 | 2.14 | 0.62 | 0.59 | 5.26 | 5.39 | 10.29 | 10.38 | 42.52 | 43.57 | 13.94 | 13.79 | 1.58 | 1.34 | 2.30 | 2.40 | 1.12 | 1.01 | 5.67 | 5.20 | 2.36 | 2.20 | 2.15 | 2.06 | 1.95 | 1.78 | Week 0 | Average values of % peak areas in group | |
| 5.38 | 3.18 | 21.27 | 12.65 | 56.17 | 65.35 | 1.52 | 1.13 | 2.89 | 3.63 | 4.59 | 4.26 | 2.65 | 0.94 | 13.33 | 7.32 | 9.75 | 12.01 | 38.34 | 42.31 | 11.53 | 12.44 | 1.08 | 1.26 | 1.74 | 1.52 | 0.64 | 0.77 | 2.79 | 3.21 | 1.28 | 1.36 | 0.91 | 1.35 | 1.06 | 1.11 | Week 1 | ||
| 5.73 | 3.10 | 19.21 | 12.64 | 57.53 | 65.64 | 2.49 | 0.78 | 4.15 | 2.92 | 5.82 | 3.51 | 2.68 | 0.85 | 12.98 | 7.02 | 10.23 | 11.74 | 37.33 | 43.24 | 10.04 | 12.81 | 0.78 | 1.34 | 1.34 | 1.77 | 0.52 | 0.89 | 1.96 | 3.70 | 0.96 | 1.57 | 0.73 | 1.47 | 0.85 | 1.31 | Week 2 | ||
| 5.04 | 2.90 | 19.03 | 12.50 | 58.71 | 64.58 | 1.44 | 0.84 | 2.33 | 2.07 | 3.41 | 2.43 | 1.97 | 0.68 | 10.53 | 5.15 | 9.99 | 10.21 | 38.63 | 40.57 | 13.00 | 13.63 | 1.53 | 1.55 | 2.04 | 2.58 | 0.78 | 1.00 | 3.89 | 5.55 | 1.72 | 2.38 | 1.22 | 2.15 | 1.37 | 2.08 | Week 3 | ||
| 5.54 | 3.16 | 17.15 | 11.02 | 58.52 | 66.48 | 1.43 | 0.54 | 3.02 | 2.22 | 4.34 | 2.72 | 1.90 | 0.59 | 10.87 | 5.90 | 10.60 | 11.84 | 39.15 | 43.41 | 11.50 | 13.51 | 1.13 | 1.45 | 2.03 | 2.23 | 0.82 | 1.02 | 3.44 | 4.59 | 1.52 | 1.99 | 1.12 | 1.80 | 1.26 | 1.68 | Week 4 | ||
| 5.82 | 3.20 | 17.83 | 10.00 | 57.31 | 66.74 | 1.64 | 0.65 | 3.41 | 2.76 | 5.37 | 3.37 | 2.41 | 0.68 | 12.12 | 6.08 | 9.48 | 11.57 | 38.08 | 43.23 | 12.02 | 13.50 | 1.11 | 1.38 | 1.77 | 2.01 | 0.55 | 0.85 | 2.81 | 4.17 | 1.31 | 1.83 | 1.03 | 1.74 | 1.10 | 1.51 | Week 5 | ||
| 6.59 | 2.72 | 19.18 | 11.27 | 54.84 | 67.53 | 1.83 | 0.96 | 3.58 | 3.28 | 5.58 | 3.66 | 2.63 | 0.84 | 12.67 | 6.32 | 9.94 | 13.14 | 36.76 | 41.44 | 10.97 | 12.12 | 0.94 | 1.12 | 1.79 | 1.92 | 0.60 | 0.76 | 2.64 | 3.80 | 1.26 | 1.54 | 0.97 | 1.48 | 1.22 | 1.38 | Week 6 | ||
| 4.97 | 2.84 | 13.25 | 9.33 | 61.70 | 68.89 | 1.77 | 1.33 | 4.49 | 4.67 | 5.90 | 4.71 | 1.40 | 0.77 | 8.63 | 6.01 | 11.73 | 13.88 | 37.48 | 40.68 | 11.55 | 11.25 | 0.96 | 1.04 | 1.74 | 1.60 | 0.60 | 0.80 | 2.94 | 3.00 | 1.43 | 1.32 | 1.24 | 1.41 | 1.35 | 1.21 | Week 7 | ||
| ↑0.002 | ↑0.002 | ↓<0.01 | ↑0.007 | ↑0.011 | ↑0.011 | ↑0.000 | ↑0.000 | ↑0.010 | ↓0.001 | ↓0.041 | ↓0.011 | ↓0.039 | ↓0.009 | ↓0.004 | ↓0.017 | ↓0.002 | ↓0.023 | Group | FDR adjusted P-value | |||||||||||||||||||
| 0.354 | 0.220 | ↓0.015 | 0.163 | 0.207 | 0.301 | ↑0.027 | ↑0.027 | 0.176 | 0.271 | ↓0.050 | ↓0.027 | 0.301 | 0.174 | 0.163 | 0.174 | 0.163 | 0.174 | Progression | ||||||||||||||||||||
Significant p-values are highlighted in bold (p<0.05) (peaks 2, 3, 4, 5, 6, 7, 8, 9, 10 and S2 are significantly decreased and peaks 11, 12, 14, 15, 17, 18, S3B and S4 are significantly increased).